Biotech Showcase™ 2016: Interview: F-star CEO details asset-centric ambitions

February 24, 2016
Unveiling its second asset-centric deal, F-star CEO Dr. John Haurum reveals to Mike Ward, global director of content for Informa's pharma insights products, how the company is looking to raise an additional USD 30 million this year to help the company move some of its own programs into the clinic within 18 months. Dr. Haurum describes differences in the deals involving F-star alpha, an option deal with Bristol-Myers Squibb, and F-star beta which will see AbbVie get access to assets that will allow it to create bispecific antibodies targeting two particular immuno-oncology checkpoints. Find more videos and articles at http://www.partnering360.com/insight For more information on Biotech Showcase™, visit our webpage: http://www.ebdgroup.com/bts/index.php
Previous Video
Biotech Showcase™ 2016: Interview: LSE stakes claim as source of patient capital for biotechs
Biotech Showcase™ 2016: Interview: LSE stakes claim as source of patient capital for biotechs

Biotech and medtech companies looking to tap into the deep pools of US capital should consider a London lis...

Next Video
Biotech Showcase™ 2016: Interview: Q BioMed accelerates advances in vascular therapeutics
Biotech Showcase™ 2016: Interview: Q BioMed accelerates advances in vascular therapeutics

Ensuring that all the necessary resources are in place to build a sustainable business is a key challenge f...